The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Effect of alpha-1 antitrypsin and alpha-1-acid glycoprotein levels on prognosis in patients with COPD exacerbation and COPD-community-acquired pneumonia
Aims: Chronic obstructive pulmonary disease (COPD) is the most frequent comorbid condition that is present in patients with pneumonia. An exacerbations of chronic obstructive pulmonary disease (ECOPD) and Comminity-acquired pneumonia (CAP) are associated with high rates of hospitalizations, costs, and morbidity. Plasma levels of orosomucoid and Alpha-1 antitrypsin (AAT), also known as Alpha-1-acid glycoprotein (AGP), increase in response to inflammation and tissue necrosis. The purpose of this study is to evaluate the impact of markers in patients with ECOPD and COPD with pneumonia .
Methods: To compare the levels of AAT, and AGP, between patients diagnosed with ECOPD only and patients diagnosed with COPD and pneumonia.
Results: The study included 14 female and 22 male volunteers. The mean gender and age of groups 1 and 2 were similar. There was no statistical difference in laboratory values between the groups.
Conclusion: Alpha-1-acid glycoprotein and AAT are acute-phase proteins elevated in various inflammatory conditions such as infections, trauma, and chronic diseases such as COPD. More studies are needed on their usefulness for monitoring and/or treatment in daily practice.

1. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronicobstructive pulmonary disease: time for its revision. Am J Respir CritCare Med. 2022;206(11):1317-1325.
2. Crisafulli E, Manco A, Ferrer M, et al. Pneumonic versus nonpneumonicexacerbations of chronic obstructive pulmonary disease. Semin RespirCrit Care Med. 2020;41(6):817-829.
3. Ioachimescu OC, Stoller JK. A review of alpha-1 antitrypsin deficiency.COPD. 2005;2(2):263-275.
4. Restrepo MI, Sibila O, Anzueto A. Pneumonia in patients with chronicobstructive pulmonary disease. Tuberc Respir Dis. 2018;81(3):187-197.
5. Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severityclassification of chronic obstructive pulmonary disease exacerbations:the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251-1258.
6. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for ChronicObstructive Lung Disease 2023 Report: GOLD Executive Summary. EurRespir J. 2023;61(4):2300239.
7. Barnes PJ. Inflammatory mechanisms in patients with chronicobstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.
8. Pneumonia in adults: diagnosis and management. National Institute forHealth and Care Excellence (NICE). NICE Guideline. 2023. No. 19. Lastupdated: 31 October 2023.
9. Luo Z, Lei H, Sun Y, Liu X, Su DF. Orosomucoid, an acute responseprotein with multiple modulating activities. J Physiol Biochem.2015;71(2):329-340.
10. Ioachimescu OC, Stoller JK. A review of alpha-1 antitrypsin deficiency.COPD. 2005;2(2):263-275.
11. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association betweenchronic obstructive pulmonary disease and systemic inflammation: asystematic review and a metaanalysis. Thorax. 2004;59(7):574-580.
Volume 2, Issue 1, 2024
Page : 11-13